Orizon Valorizacao de Residuos SA: Swaps of Upsides with Vital — Reiterate Buy, Increasing PT
Institutional-grade analysis used by equity desks before repricing events. 17 pages.
Report fact snapshot
- Publisher
- UBS
- Date
- 2026-06-11
- Type
- Market Report
- Region
- Brazil
- Sector
- Utilities, Real Estate
- Companies
- Orizon Valorizacao de Residuos SA, Vital
- Key signal
- $97
Market is pricing this as noise.
Data shows a structural shift is underway.
Sector models are broken — re-rating is imminent.
Based on UBS research, June 2026 data and regional breakdowns
Key Signals
Market is pricing this as noise.
Data shows a structural shift is underway.
Why it matters: Identifies the exact point where consensus models diverge from actual data.
A re-rating catalyst is approaching.
Consensus has not yet reflected this shift.
Why it matters: Frames the catalyst window before violent repricing begins.
Winners are concentrated in this space.
Specific companies are structurally outperforming.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus.
What You Gain From This Report
Decision Insight
Mispricing is not yet reflected in consensus models.
Missed Risk
Without the full report, you miss the company-level breakdown that separates winners from losers.
Timing Advantage
The catalyst window is open now — consensus repricing will close it within quarters.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Mispricing windows like this typically precede sector re-rating events.
Early positioning in structural winners often leads to outsized returns when consensus catches up.
The catalyst window narrows as monthly data becomes consensus, making near-term positioning critical.
Report Summary
UBS raises Orizon's price target to R$97/share (from R$92) and reiterates Buy, incorporating the Vital merger (expected to close by end-2Q26 after CADE approval) and positive earnings revisions from LRCAP auction wins. The merged entity offers a more defensive, tariff-anchored earnings profile with one of the highest real IRRs in UBS's coverage at 12%.
Institutional Content Below
Full PDF (17 pages), valuation models, broker logic, and detailed charts.
Key Takeaways
- Vital merger expected to close by end-2Q26 after CADE approval; Vital brings a more defensive, tariff-anchored business model (86.5% of gross profit from Integrated Management) with 5.5 mn tons disposed and R$520 mn EBITDA in FY2025
- Biomethane business enters its first full operating year at scale in 2026, with Paulínia and Jaboatão plants online plus Vital's GBio pipeline adding Macaúbas (90,000 m³/day), Ecourbis II (20,000 m³/day), and Juiz de Fora (30,000 m³/day)
- Valuation at 9x EV/EBITDA on 2027E EBITDA yields R$97/share PT; stock has rallied 16% since Vital announcement but still offers 12% real IRR, one of the highest in UBS's Brazil coverage
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the UBS Orizon Valorizacao de Residuos SA report. It helps users review Orizon Valorizacao de Residuos SA: Swaps of Upsides with Vital — Reiterate Buy, Increasing PT coverage, key takeaways, and related broker or sector research paths across Waste management, Biomethane expansion, M&A integration; Orizon Valorizacao de Residuos SA, Vital.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.